Ability of rabies vaccine strains to elicit cross-neutralising antibodies

Developments in Biologicals

Volumn 125, Issue , 2006, Pages 185-193

  Brookes, S M ^a   Healy, D M ^a   Fooks, A R ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

Cross neutralisation; Lyssaviruses; Vaccines

Indexed keywords

RABIES VACCINE; VIRUS ANTIBODY;

ANIMAL; BAT; CAT; CONFERENCE PAPER; CROSS REACTION; DOG; FEMALE; HUMAN; IMMUNOLOGY; MALE; RABIES VIRUS; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; CATS; CHIROPTERA; CROSS REACTIONS; DOGS; FEMALE; HUMANS; LYSSAVIRUS; MALE; RABIES VACCINES; RHABDOVIRIDAE INFECTIONS;

EID: 33745519542     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (34)

1. Aubert M: Practical significance of rabies antibodies in cats and dogs. Rev Sci Tech 1992; 11: 735-760.
2. Fooks AR, McElhinney LM, Brookes SM, Johnson N, Keene V, Parsons G, Soldan A: Rabies antibody testing and the UK Pet Travel Scheme. Vet Rec 2002; 150 (14): 428-430.
3. Schweitzer K, Moore S, Bausch L, Davis R: Dogs and cats with repeat low rabies antibody levels studied. Kansas Vet Quart. 2003; 6 (1), 4-5. Accessed on 5/12/05 http://www.vet.ksu.edu/features/VetQuarterly/KVQSpr03.pdf.
4. Aubert MFA: Can vaccination validated by the titration of rabies antibodies in serum of cats and dogs be an alternative to quarantine measures? Abstr Hyg Comm Dis 1993; 68 (6): R1-R22.
5. Fooks AR, Brookes SM, Johnson N, McElhinney LM, Hutson AM: European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 2003; 131 (3): 1029-1039.
6. Ronsholt L, Sorenson KJ, Bruschke CJM, Wilenberg GJ, Van Oirschot JT, Johnstone P, Whitby JE, Bourhy H: Clinically silent rabies infection in (zoo) bats. Vet Rec 1998; 19: 519-520.
7. Ronsholt L: A new case of European Bat Lyssavirus (EBL) infection in Danish sheep. Rabies Bulletin Europe 2002; 2: 15.
8. Muller T, Cox J, Peter W, Schafer R, Johnson N, McElhinney LM, Geue JL, Tjornehoj K, Fooks AR: Spill-over of European bat lyssavirus type 1 into a stone marten (Martes foina) in Germany. J Vet Med B Infect Dis Vet Public Health. 2004 Mar; 51 (2): 49-54.
9. Tjornehoj K, Ronsholt L, Fooks AR: Antibodies to EBLV-1 in a domestic cat in Denmark. Vet Rec 2004; 155 (18): 571-572.
10. th Annual Rabies in the Americas Conference, 2001, p 47.
11. Daoust PY, Wandeler AI, Casey GA: Cluster of rabies cases of probable bat origin among red foxes in Prince Edward Island, Canada. J Wildl Dis 1996; 32 (2): 403-406.
12. Mayen F: Haematophagous bats in Brazil, their role in rabies transmission, impact on public health, livestock industry and alternatives to an indiscriminat reduction of bat population. J Vet Med B Infect Dis Vet Public Health 2003; 50 (10): 469-472.
13. Amasino CF, Gury Dohmen F, de Gaetano J, Mena Segura C, Palazzolo A: A case of bat rabies in a cat in the province of Buenos Aires, Argentina. Rev Sci Tech 2003; 22 (3): 1021-1027.
14. Harris SL, Brookes SM, Jones G, Jolliffe TA, Aegerter JN, Smith GC, Moore NP, Mackie I, Swift SM, Racey PA, Fooks AR: Res Vet Sci 2005; 78 (Suppl. A): 30.
15. Brookes SM, Aegerter JN, Smith GC, Healy DM, Jolliffe TA, Swift SM, Mackie U, Pritchard JS, Racey PA, Moore NP, Fooks AR: European bat lyssavirus in Scottish bats. Emerg Infect Dis 2005; 11 (4): 572-578.
16. Fooks AR, Brookes SM, Healy D, Smith GC, Aegerter J, Harris SL, Jones G, Brash M, Racey P, Swift S, Mackie I, Pritchard S, Landeg F: Detection of antibodies to EBLV-2 in Daubenton's bats in the UK. Vet Rec 2004; 154 (8): 245-246.
17. Harris SL, Brookes SM, Jones G, Huston AM, Fooks AR: Passive surveillance for European bat lyssaviruses in UK bats 1987-2004. The Veterinary Record (in press).
18. Brown M: Bat Casualty Analysis 2003. Bat Care News 2004; 34: 12-18 -
19. Bat Care News 36: 10-19.
20. Badrane H, Bahloul C, Perrin P, Tordo N: Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001; 75 (7): 3268-3276.
21. Fooks AR: The challenge of Emerging Lyssaviruses. Expert Rev Vaccines 2004; 3 (4): 89-92.
22. Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS, Rupprecht CE: Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 2005; 111 (1): 44-54. Epub 2005 Apr 26.
23. Rooijakkers EJ, Nieuwenhuijs JH, Vermeulen AA, van Steenis G, Osterhaus AD: Potency of veterinary rabies vaccines in The Netherlands: a case for continued vigilance. Vet Q 1996; 18 (4): 146-150.
24. Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR: Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 2005; 23 (32): 4101-4109.
25. Cliquet F, Aubert M, Sagne L: Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 1998; 212 (1): 79-87.
26. th edition, 2000.
27. http://www.oie.int/eng/normes/mmanual/A_00042.htm.
28. Müller T, Burow J, Schameitat A, Selhorst T, Vos A: Cross-reactive antigenicity in orally vaccinated foxes and raccoon dogs against European bat lyssavirus type 1 and 2, in Dodet B, Schudel A, Pastoret PP, Lombard M (eds): Rabies in Europe. Dev Biol (Basel). Basel, Karger, 2006, vol 125, pp 195-204.
29. Herzog M, Fritzell C, Lafage M, Montano Hirose JA, Scott-Algara D, Lafon M: T and B cell human responses to European bat Lyssavirus after post-exposure rabies vaccination. Clin Exp Immunol 1991; 85 (2): 224-230.
30. Bunschoten H, Klapmuts RJ, Claassen IJ, Reyneveld SD, Osterhaus AD, Uytdehaag FG: Rabies virus-specific human T cell clones provide help for an in vitro antibody response against neutralising antibody-inducing determinants of the viral glycoprotein. J Gen Virol 1989; 70: 1513-1521.
31. Briggs DJ, Smith JS, Mueller FL, Schwenke J, Davis RD, Gordon CR, Schweitzer K, Orciari LA, Yager PA, Rupprecht CE: A comparison of two serological methods for detecting the immune response after rabies vaccination in dogs and cats being exported to rabies-free areas. Biologicals. 1998; 26 (4): 347-355.
32. Brookes SM and Fooks AR: Occupational lyssavirus risks and post-vaccination monitoring, in Dodet B, Schudel A, Pastoret PP, Lombard M (eds): Rabies in Europe. Dev Biol (Basel). Basel, Karger, 2006, vol 125, pp 165-173.
33. Kuweit et al: Early/High and Low/Late Responders among HDCS Vaccinees? in Kuwert EK, Wiktor TJ, Koprowski H (eds): Cell culture rabies vaccines & their protective effect in Man. Proceedings of WHO Consultations, Essen 1980. International Green Cross, 1981, pp 100-107.
34. Smith GC, Brookes SM, Harris SL, Aegerter JN, Jones G, Fooks AR: EBLV-2 prevalence in Great Britain as determined by surveillance testing, in Dodet B, Schudel A, Pastoret PP, Lombard M (eds): Rabies in Europe. Dev Biol (Basel). Basel, Karger, 2006, vol 125, pp 265-271.